Bristol Myers Squibb (BMY) posted a first quarter net loss attributable to Bristol Myers Squibb of $11.9 billion, or $5.89 per share, compared to net income of $2.3 billion, or $1.07 per share, a year ago. On a non-GAAP basis, net loss attributable to Bristol Myers Squibb was $8.9 billion, or $4.40 per share, compared to net profit of $4.3 billion, or $2.05 per share, last year. On average, 17 analysts polled by Thomson Reuters expected the company to report a loss per share of $4.44, for the quarter. Analysts' estimates typically exclude special items.
Net product sales were $11.56 billion compared to $11.05 billion, last year. Revenues were $11.9 billion, an increase of 5% or 6% when adjusted for foreign exchange impacts, primarily driven by Eliquis, Reblozyl and Opdualag, partially offset by Opdivo and Revlimid. Analysts on average had estimated $11.46 billion in revenue. U.S. revenues increased 7% to $8.5 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.